Nandini Raghavan

Development and evaluation of a multiplexed mass spectrometry based assay for measuring candidate peptide biomarkers in Alzheimer's Disease Neuroimaging Initiative (ADNI) CSF

Daniel S. Spellman, Kristin R. Wildsmith, Lee Honigberg et al. · PROTEOMICS - CLINICAL APPLICATIONS · 2015 · 169 citations · Full text

Life Sciences, Neurology, Neuroscience +17

Sparse learning and stability selection for predicting MCI to AD conversion using baseline ADNI data

Jieping Ye, Michael Farnum, Eric Yang et al. · BMC Neurology · 2012 · 146 citations · Full text

Medicine, Biostatistics, Neurology +17

Longitudinal CSF proteomics identifies NPTX2 as a prognostic biomarker of Alzheimer's disease

Ondrej Libiger, Leslie M. Shaw, Mark H. Watson et al. · Alzheimer s & Dementia · 2021 · 120 citations · Full text

Medicine, Neurology, Neuroscience +17

Findings of Efficacy, Safety, and Biomarker Outcomes of Atabecestat in Preclinical Alzheimer Disease

Reisa A. Sperling, David Henley, Paul Aisen et al. · JAMA Neurology · 2021 · 110 citations · Full text

Medicine, Neurology, Pharmacotherapy +17

The ADAS‐Cog revisited: Novel composite scales based on ADAS‐Cog to improve efficiency in MCI and early AD trials

Nandini Raghavan, Mahesh N. Samtani, Michael Farnum et al. · Alzheimer s & Dementia · 2012 · 97 citations · Full text

Medicine, Geriatric Medicine, Neurology +17